An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer

Trial Details

NCT ID

NCT06938282

Phase

PHASE2

Sponsor

Shanghai Zhongshan Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• HRS-4642

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Age: ≥18 years old, male or female;
• Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined b…
• Arm 1 included patients with locally advanced or metastatic pancreatic cancer whose imaging assessment met the guideline definition, and Arm 2 incl…
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.